Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Icahn School of Medicine at Mount Sinai
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Incyte Corporation
City of Hope Medical Center
Janssen Research & Development, LLC
AstraZeneca
AstraZeneca
Hoffmann-La Roche
M.D. Anderson Cancer Center
Bristol-Myers Squibb
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
UNC Lineberger Comprehensive Cancer Center
Hoffmann-La Roche
AstraZeneca
Hoffmann-La Roche
AstraZeneca
Wake Forest University Health Sciences
Janssen Research & Development, LLC
Hoffmann-La Roche
NRG Oncology
Roswell Park Cancer Institute
AstraZeneca
St. Jude Children's Research Hospital
AstraZeneca
National Cancer Institute (NCI)
AstraZeneca
National Cancer Institute (NCI)
AstraZeneca
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC